IDH1-mutated relapsed or refractory AML: current challenges and future prospects

The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 (IDH1(mut)), present in 7–14% of AML patients, have been discovered recently, opening the door to targeted agents aiming to...

Descripción completa

Detalles Bibliográficos
Autores principales: Megías-Vericat, Juan Eduardo, Ballesta-López, Octavio, Barragán, Eva, Montesinos, Pau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663038/
https://www.ncbi.nlm.nih.gov/pubmed/31413655
http://dx.doi.org/10.2147/BLCTT.S177913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663038/
https://www.ncbi.nlm.nih.gov/pubmed/31413655
http://dx.doi.org/10.2147/BLCTT.S177913

Ejemplares similares